Legend Biotech is scheduled to release its first-quarter 2026 financial results before the market opens on Tuesday, May 12th. Market focus is centered on the sales performance of its core product, CARVYKTI, and the company's progress toward profitability. Based on preliminary data already disclosed, CARVYKTI's net trade sales for the quarter are approximately $597 million. Regarding market expectations, analysts forecast Legend Biotech's first-quarter revenue to be around $306.5 million, representing a significant year-over-year increase of approximately 57%. The estimated loss per share is $0.17, showing improvement compared to the same period last year. Previously, some institutions had revised their Q1 earnings per share estimate for the company from a loss of $0.04 to break-even. The sales growth of CARVYKTI remains the primary highlight for the quarter. Developed in collaboration with Johnson & Johnson, the product generated sales of $306 million in the previous quarter. Although the first quarter is typically affected by seasonal factors, demand for CAR-T therapies remains robust. The preliminary sales figure of approximately $597 million far exceeded market expectations. Investors will also focus on the company's capacity expansion plans for 2026 and regulatory progress for frontline treatments. The path to profitability is another core market concern. Legend Biotech has previously reported losses with a negative net profit margin. Investors are keen to see whether operating leverage effects are beginning to materialize as sales scale increases. Furthermore, the company will hold a conference call following the earnings release, where management's outlook on full-year performance guidance and the competitive landscape for CAR-T therapies will be closely watched.